Regencell Bioscience (NASDAQ: RGC), a China-based drugmaker, has been on fire over the past 12 months, with its share price skyrocketing by more than 21,000% as of this writing (that's not a typo). A ...

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 23, 2026 deadline to file a lead plaintiff motion in ...

The Gross Law Firm issues the following notice to shareholders of Regencell Bioscience Holdings Limited (NASDAQ: RGC).

Regencell Bioscience (NASDAQ:RGC) ended a 10-day losing streak on Thursday to climb ~120%, extending its YTD jump to over 180-fold, days after the Chinese biotech blamed short sellers, among other ...

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) s ...

View Regencell Bioscience Holdings Ltd. RGC stock quote prices, financial information, real-time forecasts, and company news from CNN.

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds Regencell ...

Regencell Bioscience remains severely overvalued at a $6 billion market cap, despite having no revenue, assets, or business activity. RGC's 20-F filing revealed three material weaknesses in internal ...

Regencell Bioscience's investor website explains that it is an early-stage bioscience company working on TCM. It lists indications such as neurocognitive disorders and infectious diseases as areas of ...

Regencell Bioscience's outrageous performance in the past year is baffling. Despite the stock's sharp rise, there is little to look forward to for the drugmaker. Pfizer is a much better bet with its ...